Safety and Efficacy of YH14617 in Diabetes Mellitus

NCT01507038 · Completed

Last updated 2026-05-28

This clinical trial tests the safety and effects of the drug YH14617 in people with diabetes mellitus to see how it may influence HbA1c levels over 12 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 84 people

Who can join Ages 20–75 · all sexes

Timeline Started 2011-12 · est. completion 2015-02

Where 1 site · South Korea

What this study is testing ClinicalTrials.gov NCT01507038 ↗

Description as written by the study sponsor.

The objective of this study is to assess the safety, efficacy and pharmacokinetic of YH14617 after once weekly or biweekly injection in patients with type 2 Diabetes Mellitus to investigate the optimal recommended dosage. Study period is 20 weeks including 12 weeks of treatment period and 8weeks of follow-up period without treatment.

Treatments tested

YH14617 Drug

1mg once weekly
YH14617 Drug

1.6mg once weekly
YH14617 Drug

2mg once biweekly
Placebo Drug

Once weekly

Main thing measured	Change from baseline in HbA1c at week 12
Sponsor	Yuhan Corporation
Conditions studied	Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01507038 ↗